Cargando…

Comment on “Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6”

Detalles Bibliográficos
Autores principales:	Cattaneo, Dario, Corbellino, Mario, Cozzi, Valeria, Fusi, Marta, Gervasoni, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052541/ https://www.ncbi.nlm.nih.gov/pubmed/33864625 http://dx.doi.org/10.1007/s40262-021-00992-5

Ejemplares similares

Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data
por: Daskapan, Alper, et al.
Publicado: (2019)

Darunavir does not prevent SARS-CoV-2 infection in HIV patients
por: Riva, Agostino, et al.
Publicado: (2020)

Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts
por: Cattaneo, Dario, et al.
Publicado: (2020)

Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6
por: Cojutti, Pier Giorgio, et al.
Publicado: (2020)

Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6”
por: Cojutti, Pier Giorgio, et al.
Publicado: (2021)

Does lopinavir really inhibit SARS-CoV-2?
por: Cattaneo, Dario, et al.
Publicado: (2020)

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
por: Cattaneo, Dario, et al.
Publicado: (2020)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
por: Dickinson, L, et al.
Publicado: (2010)

Darunavir pharmacokinetics throughout pregnancy and postpartum
por: Lambert, John, et al.
Publicado: (2014)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

The Issue of Pharmacokinetic-Driven Drug-Drug Interactions of Antibiotics: A Narrative Review
por: Cattaneo, Dario, et al.
Publicado: (2022)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Profile of darunavir in the management of treatment-experienced HIV patients
por: Wolfe, Cameron, et al.
Publicado: (2009)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Multidrug-resistant HIV viral rebound during early syphilis: a case report
por: Giacomelli, Andrea, et al.
Publicado: (2020)

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily
por: Zorrilla, CD, et al.
Publicado: (2014)

Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?
por: Gervasoni, Cristina, et al.
Publicado: (2015)

Combating HIV resistance – focus on darunavir
por: Tremblay, Cécile L
Publicado: (2008)

Role of darunavir in the management of HIV infection
por: Lascar, R Monica, et al.
Publicado: (2009)

Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations
por: Stillemans, Gabriel, et al.
Publicado: (2020)

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy
por: Colbers, Angela, et al.
Publicado: (2015)

Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
por: Dobroszycki, Joanna, et al.
Publicado: (2011)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
por: Kakuda, Thomas, et al.
Publicado: (2012)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
por: Neely, Michael, et al.
Publicado: (2009)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014)

Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model
por: Stillemans, Gabriel, et al.
Publicado: (2020)

Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir
por: Opsomer, Magda, et al.
Publicado: (2018)

Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy
por: Marcelin, AG, et al.
Publicado: (2010)

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
por: Ucciferri, Claudio, et al.
Publicado: (2016)

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients
por: Fabbiani, Massimiliano, et al.
Publicado: (2023)

Development of an HPLC–UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients()
por: Charbe, Nitin, et al.
Publicado: (2016)

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
por: Moltó, J, et al.
Publicado: (2010)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients
por: López-Ruz, Miguel A., et al.
Publicado: (2018)

Correction to: Evaluation of Cardiovascular Disease Risk in HIV‑1–Infected Patients Treated with Darunavir
por: Opsomer, Magda, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bappmah1956vaa0jktjg2p8k9j